evipedia.ai
← Back

Cissus quadrangularis for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L / Opus 5.5

Also known as: Veldt Grape, Hadjod, Asthisamharaka, Asthi Shrinkhala, Pirandai, Devil’s Backbone, Adamant Creeper, Winged Treebine, Cissus, CQ, CQR-300, Cal-Z-Bone

Motivation

Cissus quadrangularis (veldt grape) is a succulent vine of the grape family whose four-sided stems have long been used as a folk remedy for broken bones. Today it is sold as a dietary supplement, mainly to support bone healing, ease joint discomfort and help with weight control. For people focused on staying healthy into later life, its possible role in keeping bones strong and weight in check is the main draw. Plant compounds in the stem appear to encourage bone-building cells and calm inflammation.

In India the plant is called “Hadjod”, meaning “bone joiner”, and it has a place in traditional medicine across South Asia, Southeast Asia and Africa. Interest outside those traditions grew when strength athletes adopted it for sore joints and when a series of weight-loss studies drew attention to its possible effects on body fat.

This review examines what human studies show about the plant’s effects on bone, joints and body weight, how strong and how independent that evidence is, what is known about its safety over months of use, and how it is taken in practice.

Benefits - Risks - Protocol - Conclusion

This section lists overview-level narrative reviews that discuss Cissus quadrangularis by name.

No relevant content was found from Peter Attia, Chris Kresser or Lifespan.io; Rhonda Patrick’s FoundMyFitness only reproduces a listener question naming Cissus without discussing it; Andrew Huberman mentions Cissus only briefly, as one of three serotonin supplements in a broad episode on brain chemistry; and Life Extension references Cissus only in citation lists and product listings rather than in an article. Only three items are listed because the remaining candidates were single primary trials or passing references without discussion rather than overview-level material, and the list is not padded with them.

Grokipedia

  • Cissus quadrangularis

    Encyclopedic overview of the plant’s taxonomy, chemical constituents, traditional uses, supplement forms and reported safety, including possible interaction with diabetes medications and caution in pregnancy.

Examine

  • Cissus quadrangularis

    Independent summary rating the human evidence as preliminary, flagging financial bias and a possible fiber-driven appetite effect in the weight trials, and noting rodent sedation at high doses.

ConsumerLab

No dedicated ConsumerLab article on Cissus quadrangularis exists; the site covers it only as one ingredient within a product-specific answer on the bone supplement OsteoMD.

Systematic Reviews

Systematic reviews and meta-analyses of human trials of Cissus quadrangularis for bone, weight and metabolic outcomes are listed below.

Mechanism of Action

Cissus quadrangularis stems contain flavonoids (plant pigments such as quercetin and kaempferol), stilbenes (resveratrol and related quadrangularins), phytosterols (plant cholesterol-like compounds such as β-sitosterol), triterpenes, plant steroids, vitamin C and calcium. Proposed mechanisms fall into three groups:

  • Bone: cell and rodent studies show more osteoblasts (bone-building cells) and more mineral deposition, partly by boosting IGF-1 (insulin-like growth factor 1, a growth signal for bone cells) (Muthusami et al., 2011), and fewer osteoclasts (bone-resorbing cells).
  • Inflammation: extracts dampen IL-1β (interleukin-1 beta, an inflammatory messenger) responses in cartilage cells via p38 MAPK (mitogen-activated protein kinase, a cellular stress-signaling pathway) (Kanwar et al., 2015).
  • Metabolism: in-vitro inhibition of fat- and starch-digesting enzymes, higher blood serotonin (Kuate et al., 2015) and adiponectin (a fat-cell hormone that improves insulin sensitivity) (Nash et al., 2019) in trials run with the extract’s marketer, and higher UCP1 (uncoupling protein 1, which lets fat cells burn energy as heat) in human fat cells (Chatree et al., 2021).

Competing explanations exist. The weight effect may partly reflect a gum-like fiber taken with water before meals that reduces food intake. The rise in parathyroid hormone could reflect either bone-building signaling or a bone-resorbing state.

As a whole-plant preparation, Cissus has no single defined half-life or selectivity. In rats, quercetin and resveratrol from the extract are absorbed quickly but broken down by liver enzymes (Dadge et al., 2023); human pharmacokinetic data are absent.

Historical Context & Evolution

Originally a traditional remedy, it appears in Ayurvedic texts as “Asthisamharaka” (that which prevents bone destruction), and Indian bonesetters applied stem paste to fractures and gave stem preparations orally. Thai traditional medicine uses it for hemorrhoids, and in Cameroon and other African countries the stem is eaten and used for pain and digestive complaints.

Indian animal studies from the 1960s reported faster fracture healing in rats and dogs given the plant (Udupa & Prasad, 1964), giving the traditional claim a first experimental basis. Small Indian jaw-fracture studies followed in the 2010s, reporting less pain and faster healing but with few patients and little blinding (Singh et al., 2013).

Two currents then brought Cissus into health optimization. From the mid-2000s, sports-supplement companies marketed it for joint and tendon recovery, building on the bone-healing reputation. Meanwhile, a Cameroon research group, working with the extract’s U.S. marketer, published placebo-controlled weight-loss trials of a proprietary extract, CQR-300, reporting reductions in weight, blood fats and blood sugar (Kuate et al., 2015).

Later evidence tempered some claims. A large Thai trial found no benefit for acute hemorrhoids compared with placebo (Panpimanmas et al., 2010), and a placebo-controlled trial in postmenopausal women found slower bone turnover but no change in bone density (Benjawan et al., 2022). A 2025 meta-analysis added a new question by finding higher parathyroid hormone levels (Na Takuathung et al., 2025). None of these findings closes the case either way: the fracture and weight evidence remains small, commercially linked and largely unreplicated.

Expected Benefits

High 🟩 🟩 🟩

Body Weight and Body Fat Reduction

Several placebo-controlled trials of a proprietary stem-and-leaf extract (CQR-300, 300 mg daily) reported lower body weight, body fat and waist size over 8–16 weeks (Nash et al., 2019); an independent Thai randomized trial found waist and hip reductions from baseline (Chatree et al., 2021). Nearly all trials come from one Cameroon research group using extract supplied by its U.S. marketer, Gateway Health Alliances, a direct financial conflict of interest. Part of the effect may reflect reduced food intake from gum-forming fiber.

Magnitude: Body fat fell 8.9% (body-fat scale) and 12.8% (dual-energy X-ray scan) versus about 1% with placebo at 8 weeks (Nash et al., 2019); pooled combination products gave −5.19 kg versus placebo (Sawangjit et al., 2017).

Improved Blood Fats and Blood Sugar

The same trials reported lower LDL cholesterol (low-density lipoprotein, the main artery-clogging cholesterol carrier), triglycerides, total cholesterol and fasting glucose, and higher HDL cholesterol (high-density lipoprotein, the protective carrier) (Nash et al., 2019). The pooled lipid and glucose estimates come from combination products (Cissus with Irvingia gabonensis or other herbs), not Cissus alone. The same single-group, supplier-linked conflict applies, and no independent group has replicated these findings.

Magnitude: Pooled versus placebo: LDL −14.43 mg/dL, triglycerides −37.50 mg/dL, total cholesterol −50.50 mg/dL, fasting glucose −10.39 mg/dL (Sawangjit et al., 2017).

Medium 🟩 🟩

Reduced Appetite and Energy Intake

In a 16-week placebo-controlled trial of 248 overweight or obese adults, 300 mg daily CQR-300 lowered self-reported energy intake and raised satiety, alongside higher GLP-1 (glucagon-like peptide-1, a fullness hormone) and lower DPP-4 (dipeptidyl peptidase-4, the enzyme degrading it) activity (Youovop et al., 2025). An earlier trial reported higher blood serotonin (Kuate et al., 2015). The extract was supplied by its marketer, Gateway Health Alliances, to the same Cameroon group, and no independent trial has measured appetite. Gum-forming fiber taken before meals may contribute.

Magnitude: Energy intake fell 17.5% and satiety rose 27.4% with CQR-300 over 16 weeks, with GLP-1 up 42.2 pg/mL and DPP-4 activity down 17.8% versus placebo (Youovop et al., 2025).

Lower Blood Pressure

In an 8-week placebo-controlled trial of 67 overweight adults, 300 mg daily CQR-300 lowered systolic and diastolic blood pressure (Nash et al., 2019). This is the only trial to report blood pressure, and it comes from the supplier-linked Cameroon group. The CQR-300 group started with higher systolic pressure than the placebo group, so part of the fall may reflect that starting difference or accompanying weight loss.

Magnitude: Systolic pressure fell 11.6 mmHg versus 1.4 mmHg with placebo, and diastolic pressure 4.1 mmHg versus 0.1 mmHg, over 8 weeks (Nash et al., 2019).

Low 🟩

Faster Bone Healing After Fracture or Oral Surgery ⚠️ Conflicted

Small trials in jaw fractures and jaw-bone lengthening before implants reported less pain and faster healing on X-rays (Singh et al., 2013; Altaweel et al., 2021). A randomized pilot found no clinical or X-ray benefit (Nayak & R, 2020). Net reading: pain relief is plausible, faster bone union unproven.

Magnitude: Combined with Boswellia serrata in an unblinded trial with an industry co-author, wrist-fracture union scores reached 7.96 versus 5.54 with standard care at 60 days (Mungara et al., 2026).

Slower Bone Turnover in Postmenopausal Osteopenia

In 134 postmenopausal women with osteopenia (bone density below normal but above osteoporosis), 1.2–1.6 g daily stem powder for 24 weeks lowered a bone-formation marker and held a bone-breakdown marker stable, while both rose with placebo (Benjawan et al., 2022). Bone density did not differ from placebo.

Magnitude: P1NP (procollagen type 1 N-terminal propeptide, a bone-formation marker) fell 9.95% from baseline with 1.6 g daily at 24 weeks, significantly different from placebo; bone density showed no between-group difference.

In 29 exercise-trained men with chronic joint pain, 3.2 g daily for 8 weeks lowered WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index, a validated pain and function score) scores (Bloomer et al., 2013). With no placebo group, expectation effects cannot be excluded.

Magnitude: Total WOMAC score fell from 25.4 to 17.4 (about 31%) over 8 weeks.

Speculative 🟨

Tendon and Ligament Repair

Popular in strength sports for connective-tissue recovery. The basis is anecdotal and rests on rodent anti-inflammatory data; no controlled human study has measured tendon or ligament healing.

Lower Systemic Inflammation and Oxidative Stress

Cell and rodent studies show reduced inflammatory signaling; one supplier-linked formulation trial reported lower C-reactive protein (a blood inflammation marker) (Oben et al., 2006). These biomarkers are unvalidated.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been studied for its effect on response to Cissus. Variants in vitamin D or calcium-sensing pathways could plausibly modify bone effects, but this remains untested.
  • Baseline biomarkers: Weight and lipid benefits were reported in people with overweight or metabolic syndrome (abdominal fat plus high blood pressure, sugar or blood fats); normal-lipid, normal-glucose adults are unstudied. Bone-marker effects appeared where turnover was already rising.
  • Sex: Evidence is split by sex: the joint-pain study enrolled only men (Bloomer et al., 2013), the osteopenia trial only postmenopausal women (Benjawan et al., 2022), and weight trials both sexes without reported sex differences.
  • Pre-existing conditions: Benefits were observed in specific settings: recent jaw fractures, jaw-bone surgery, postmenopausal osteopenia and obesity. Effects in healthy, lean, active adults are unknown.
  • Age: Weight trials enrolled adults aged 18–65, fracture trials mostly adults under 50, and the osteopenia trial women over 40. Adults over 70, at highest fracture risk, are largely unstudied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been shown in more than one controlled trial to occur more often with Cissus than with placebo.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or consistent observational dataset has linked Cissus to a specific adverse clinical outcome.

Low 🟥

Mild Gastrointestinal and Nonspecific Side Effects

Trials and a drug-reference monograph list flatulence, diarrhea, dry mouth, headache and insomnia, but in controlled trials these occurred at similar rates on placebo (Oben et al., 2008; Benjawan et al., 2022). A pooled review of nine randomized trials found no serious adverse effects (Sawangjit et al., 2017).

Magnitude: No serious adverse events across 1,108 trial patients; adverse event incidence equal to placebo in a 134-woman, 24-week trial.

Parathyroid Hormone Elevation

A meta-analysis found higher parathyroid hormone (which raises blood calcium, partly by releasing it from bone) with Cissus, without calcium changes (Na Takuathung et al., 2025). Sustained elevation can promote bone loss; the clinical meaning here is unknown.

Magnitude: SMD (standardized mean difference, effect size in standard-deviation units) 1.23, 95% CI (confidence interval, the range likely to contain the true value) 0.79–1.67, from two small trials; certainty very low.

Additive Blood Sugar Lowering

Trials reported lower fasting glucose, raising a theoretical risk of hypoglycemia (abnormally low blood sugar) alongside glucose-lowering drugs. A review of African herbal trials, including Cissus, listed mild hypoglycemia among side effects (Altayyar et al., 2026).

Magnitude: Fasting glucose fell 10.39 mg/dL versus placebo with combination products (Sawangjit et al., 2017); no severe hypoglycemia cases have been published.

Low Platelet Count

A single case report described thrombocytopenia (abnormally low blood platelets, which raises bleeding risk) in an older kidney transplant recipient taking Cissus for backache; counts normalized after stopping (Kulkarni & Bhat, 2020). Concurrent azathioprine and prednisolone confound attribution.

Magnitude: Not quantified in available studies. Only one case report exists, and no trial has reported platelet counts.

Speculative 🟨

Product Contamination and Adulteration

Testing of herbal weight-loss supplements, including Cissus products, most often detected manganese, aluminum and iron (Barrella et al., 2017). No human harm has been linked to contaminated Cissus products; the basis is product analysis only.

Sedation at High Doses

Rodent studies summarized by Examine suggest sedative and muscle-relaxant effects at high doses. The basis is animal data only; no human reports exist.

Effects on Pregnancy and Fetal Development

In pregnant rats, a Cissus extract accelerated fetal bone growth (Potu et al., 2008), showing activity on developing tissue. No human pregnancy data exist.

Unknown Long-Term Organ Safety

Rats showed no toxicity at 2,500 mg/kg daily for 90 days in a study affiliated with the extract’s marketer (Kothari et al., 2011). No human study exceeds 24 weeks.

Allergic Reactions

A drug-reference monograph lists allergic reactions, which can be serious; this listing is the only basis. No case reports exist, and allergy antibody testing in one trial showed no sensitization (Nash et al., 2019).

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist for Cissus. Variants in liver enzymes that clear quercetin and resveratrol could theoretically alter exposure, but none has been studied.
  • Baseline biomarkers: Parathyroid hormone already at the upper reference limit, high-normal calcium, or fasting glucose below 80 mg/dL on medication increase the relevance of the parathyroid and blood-sugar signals.
  • Sex: Pregnancy and breastfeeding are the main sex-specific concerns because of fetal bone effects in rats. Postmenopausal women, with faster bone loss, have more at stake if parathyroid hormone rises persistently.
  • Pre-existing conditions: Diabetes treated with insulin or sulfonylureas (drugs that force insulin release), primary hyperparathyroidism (overactive parathyroid glands), chronic kidney disease (which raises parathyroid hormone) and upcoming surgery increase risk relevance.
  • Age: Older adults have higher baseline parathyroid hormone, more bone fragility and greater vulnerability to hypoglycemia; trials have not included many adults over 65.

Key Interactions & Contraindications

  • Glucose-lowering drugs (metformin, insulin, glipizide, semaglutide): Caution. Additive glucose lowering may cause hypoglycemia. Weekly fasting glucose checks during the first month; prescriber dose adjustment may be needed.
  • Antihypertensive drugs (blood pressure medications: amlodipine, lisinopril, losartan): Monitor. One trial found lower blood pressure (Nash et al., 2019), so additive lowering with dizziness is possible. Home blood pressure checks during the first 2–4 weeks.
  • Lipid-lowering drugs (atorvastatin, rosuvastatin): Monitor. Possible additive lipid lowering without known harm. Lipid panel recheck after 8–12 weeks.
  • Bone-active drugs (alendronate, teriparatide, denosumab): Caution. Cissus raises parathyroid hormone, which may interfere with these drugs’ calibrated effects on bone turnover. Parathyroid hormone and calcium testing before starting and after 12 weeks.
  • Serotonergic drugs (drugs raising serotonin activity: sertraline, escitalopram, tramadol): Caution, theoretical. Cissus raised blood serotonin in trials; excess serotonin activity has not been reported. Agitation, tremor or sweating are the warning signs.
  • Over-the-counter analgesics (ibuprofen, naproxen): Monitor. No documented interaction; both are used for joint pain, and anti-inflammatory drugs may slow fracture healing, confounding assessment of Cissus. Logging analgesic use alongside pain scores separates the two effects.
  • Over-the-counter antacids and calcium supplements (calcium carbonate): Monitor. No documented interaction; in bone stacks, high calcium intake plus rising parathyroid hormone could cause hypercalcemia (high blood calcium). Periodic serum calcium checks detect this.
  • Glucose-lowering supplements (berberine, chromium, cinnamon, alpha-lipoic acid): Caution. Additive effect on blood sugar with hypoglycemia risk. Introductions spaced several weeks apart with fasting glucose monitoring.
  • Serotonin-raising supplements (5-HTP (5-hydroxytryptophan, a serotonin precursor), St. John’s wort, L-Tryptophan): Caution, theoretical. Additive serotonin activity. Staggered introduction avoids stacking during the first month; agitation or tremor signal excess.
  • Weight-loss herbal combinations (Irvingia gabonensis, green tea extract): Monitor. Larger reductions in weight, cholesterol and glucose were reported with Irvingia (Oben et al., 2008); green tea extract adds a separate liver-injury risk. One product introduced at a time; liver enzymes checked after 8–12 weeks.
  • Fasting, very-low-carbohydrate diets and prolonged endurance exercise: Caution. These lower blood glucose independently and may compound hypoglycemia on glucose-lowering medication. Glucose monitoring during adaptation.
  • Elective surgery: Caution. Effects on blood sugar, one reported case of low platelet count, and unknown effects on anesthesia. Standard herbal practice is stopping at least 2 weeks before scheduled surgery.

Populations who should avoid Cissus quadrangularis:

  • Pregnant or breastfeeding women
  • Children and adolescents under 18 years
  • People with primary hyperparathyroidism or parathyroid hormone above the reference range (>65 pg/mL)
  • People with hypercalcemia (high blood calcium; serum calcium >10.3 mg/dL)
  • People with chronic kidney disease stage 3b or worse (eGFR, estimated glomerular filtration rate, a kidney-function measure, <45 mL/min/1.73 m²)
  • People with insulin-treated diabetes and recurrent hypoglycemia (glucose <70 mg/dL more than once weekly)
  • Anyone within 14 days of elective surgery
  • People with known allergy to plants of the grape family (Vitaceae)

Risk Mitigation Strategies

  • Baseline and follow-up glucose checks: Fasting glucose and HbA1c (glycated hemoglobin, a 3-month blood-sugar average) before starting, plus weekly fasting glucose for 4 weeks on glucose-lowering drugs, guard against hypoglycemia.
  • Parathyroid hormone and calcium monitoring: Testing at baseline and after 12 weeks, with discontinuation if parathyroid hormone exceeds 65 pg/mL, limits potential bone loss from sustained elevation.
  • Third-party tested products: A certificate of analysis showing heavy metals below USP (United States Pharmacopeia) limits reduces manganese, aluminum and lead exposure and adulteration risk.
  • Starting at trial doses: Protocols begin at 300 mg extract or 1.2 g powder daily, increasing only after 2 weeks if tolerated, minimizing gastrointestinal upset, headache and insomnia.
  • Morning or midday dosing: A last dose before mid-afternoon reduces the insomnia reported in trials.
  • Time-limited courses: Continuous use capped at 24 weeks, the longest human safety data, followed by lab reassessment, addresses unknown long-term organ safety.
  • Pre-surgery pause: Stopping at least 14 days before elective surgery avoids unpredictable blood-sugar changes around anesthesia and fasting.

Therapeutic Protocol

  • Weight and metabolic protocol: CQR-300 extract 300 mg daily, taken with water immediately before a meal, for 8–16 weeks, as used in the Cameroon trials of Julius Oben’s group (Nash et al., 2019) and marketed by Gateway Health Alliances.
  • Fracture-healing protocol: Cissus capsules 500 mg three times daily for 6 weeks after fracture fixation, as used in an Indian jaw and facial fracture trial (Brahmkshatriya et al., 2015); Ayurvedic practitioners prescribe “Hadjod” preparations similarly.
  • Bone-turnover protocol: Dried stem powder 1.2–1.6 g daily for 24 weeks, as tested in postmenopausal osteopenia at Mahidol University, Thailand (Benjawan et al., 2022).
  • Joint-pain protocol: 3.2 g daily in divided doses for 8 weeks, as used in the University of Memphis study of exercise-trained men (Bloomer et al., 2013) and popular in strength-sport communities.
  • Serotonin and appetite approach: 300–600 mg daily with periodic cycling, as described by Andrew Huberman; the cycling schedule has no supporting data.
  • Competing approaches for bone: Conventional care uses bisphosphonates (drugs that slow bone breakdown), denosumab or teriparatide, with proven fracture reduction; integrative practitioners use Cissus alone or with calcium, vitamin D and vitamin K2. No head-to-head comparison exists.
  • Time of day: Before meals for appetite and weight effects; morning or midday to limit insomnia. Bone and joint trials did not specify timing.
  • Half-life: No human half-life has been measured for the extract; constituents such as resveratrol and quercetin are cleared within hours to about a day, supporting daily or twice-daily dosing.
  • Single versus split dose: CQR-300 was effective once daily; powder doses above 1 g were usually split into two or three doses, which may also improve tolerance.
  • Genetic polymorphisms: No gene variants are known to change the dose or response; no pharmacogenetic testing is relevant.
  • Sex: No sex-specific dosing exists. Postmenopausal women used 1.2–1.6 g for bone; weight trials used identical doses for men and women.
  • Age: Protocols for older adults typically start at the low end (300 mg extract or 1.2 g powder) given higher hypoglycemia and parathyroid sensitivity.
  • Baseline biomarkers: Elevated waist size, lipids or fasting glucose define those most likely to respond in weight trials; elevated bone-turnover markers define candidates for the bone protocol.
  • Pre-existing conditions: Use alongside glucose-lowering or bone-active drugs is typically coordinated with the prescriber; kidney disease and hyperparathyroidism weigh against use.

Discontinuation & Cycling

  • Short-term by design: Human data cover 6 weeks (fracture) to 24 weeks (bone turnover); fracture use ends with healing, while weight or bone use has no evidence supporting lifelong continuation.
  • Withdrawal effects: None reported in any trial.
  • Tapering: Not required; stopping abruptly has not caused rebound effects. For those on glucose-lowering drugs, a glucose recheck after stopping captures changing medication needs.
  • Cycling: No study has tested cycling. Cycling schedules circulating online (two weeks on, two off) rest on opinion only; periodic breaks allow lab reassessment.

Sourcing and Quality

  • Plant part and preparation: Products use dried stem powder, aqueous stem-and-leaf extracts or ethanol extracts, with differing chemical profiles. Human trial results apply only to the preparation tested and are not interchangeable.
  • Standardization: Branded ingredients include CQR-300 (Gateway Health Alliances), the extract used in the weight trials, and Cal-Z-Bone (Verdure Sciences), a standardized stem extract used in bone formulas such as OsteoMD.
  • Third-party testing: USP or NSF International certification, or a batch-specific certificate of analysis covering identity, heavy metals and microbes, indicates quality; few Cissus products carry independent seals.
  • Contaminants: Some weight-loss products have tested high for manganese and aluminum (Barrella et al., 2017). Sports-supplement blends may contain undeclared stimulants; single-ingredient products reduce this risk.
  • Traditional preparations: Ayurvedic “Hadjod” tablets from Indian pharmacies follow traditional pharmacopeia standards but often lack Western third-party testing.

Practical Considerations

  • Time to effect: Weight and waist changes appeared by week 4 in trials; fracture pain differences within 3–6 weeks; bone-turnover markers shifted by week 12. Bone density changes, if any, would take longer than the 24 weeks studied.
  • Common pitfalls: Expecting muscle-building effects (no human evidence), using it for hemorrhoids (no benefit over placebo in a large trial), assuming powder and extract doses are equivalent, and buying stimulant-laden “Cissus” stacks.
  • Regulatory status: Sold as a dietary supplement in the United States without drug approval; in India it is an Ayurvedic medicine. No regulator has approved it for fracture, bone loss or weight loss.
  • Cost and access: Inexpensive and widely available online; cost is not a barrier.
  • Research funding asymmetry: As an unpatentable plant, Cissus attracts little independent funding, while insurers and national health systems cover patented bone drugs, a structural bias that leaves trials small and mostly supplier-funded.

Interaction with Foundational Habits

  • Sleep: Direct, potentially disruptive: insomnia is among reported side effects, mechanism unknown. Protocols typically place the last dose before mid-afternoon; no study has measured sleep quality objectively.
  • Nutrition: Potentiating: weight effects appeared both with and without a calorie-controlled diet in trials, with larger absolute losses when combined (Oben et al., 2006). Taking it with water before meals may add a fiber-like fullness effect. Adequate calcium, protein and vitamin D support any bone effect.
  • Exercise: Indirect: reduced exercise-related joint pain may support training volume. Rodent data suggest sedation at high doses, so pre-workout use at high doses is untested. No study has examined effects on strength or muscle gain.
  • Stress management: None established: no study has measured cortisol or stress outcomes. The reported rise in blood serotonin has not been linked to mood or stress resilience, and blood serotonin does not reflect brain serotonin.

Monitoring Protocol & Defining Success

Baseline testing before starting typically includes fasting glucose and HbA1c, a lipid panel, parathyroid hormone, serum calcium and 25-hydroxyvitamin D, liver enzymes and kidney function, plus waist circumference and blood pressure. For bone use, panels typically add a bone-formation marker and, if not done within two years, a bone density scan.

Ongoing monitoring follows this cadence: fasting glucose weekly for the first 4 weeks if on glucose-lowering drugs; lipids, glucose, parathyroid hormone and calcium at 12 weeks; the full panel again at 24 weeks before any decision to continue; and a bone density scan 12–24 months after starting a bone protocol. Parathyroid hormone above the reference range or rising calcium are stopping signals. Success for weight means lower waist size and lipids; for bone, stable markers and density.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–90 mg/dL Detect hypoglycemia or benefit Conventional 70–99 mg/dL; 8–12 hour fast; morning draw
HbA1c 4.8–5.4% 3-month glucose trend Conventional <5.7%; pair with fasting glucose
Parathyroid hormone 20–45 pg/mL Key safety signal Conventional 15–65 pg/mL; morning fasting draw; pair with calcium and vitamin D
Serum calcium 9.2–10.0 mg/dL Detect calcium imbalance Conventional 8.6–10.3 mg/dL; albumin-corrected; fasting
25-hydroxyvitamin D 40–60 ng/mL Low vitamin D raises parathyroid hormone Conventional 30–100 ng/mL; correct before interpreting parathyroid hormone
LDL cholesterol <100 mg/dL Track lipid benefit Conventional <130 mg/dL for low risk; ApoB (apolipoprotein B, the particle count of atherogenic lipoproteins) is a useful pairing
Triglycerides <100 mg/dL Track lipid benefit Conventional <150 mg/dL; 12-hour fast
ALT 10–25 U/L Liver safety check ALT (alanine aminotransferase, a liver enzyme); conventional upper limit about 40–55 U/L
eGFR >90 mL/min/1.73 m² Kidney function, affects parathyroid hormone Conventional >60; pair with creatinine and cystatin C
P1NP No established target; track change from own baseline Bone-formation activity Morning fasting draw; pair with CTX (C-terminal telopeptide, a bone-breakdown marker)
Bone density (dual-energy X-ray scan) T-score above −1.0 Bone outcome T-score (bone density compared with a healthy young adult, in standard deviations); conventional osteopenia −1.0 to −2.5; change detectable only after 12–24 months
Waist circumference Waist-to-height ratio <0.5 Central fat outcome Conventional thresholds 102 cm men, 88 cm women; measure at the navel, same time of day
Blood pressure <120/80 mmHg Additive lowering with drugs Conventional <130/80 mmHg; seated home readings, morning

Qualitative markers to track:

  • Joint pain and stiffness during and after training
  • Appetite, portion size and between-meal hunger
  • Energy levels and daytime alertness
  • Sleep onset and sleep quality
  • Gastrointestinal comfort (gas, stool changes)
  • Functional recovery after injury (grip, range of motion, return to activity)

Emerging Research

  • Ongoing gut-hormone trial: Cissus versus Dichrostachys glomerata extract on GLP-1 and DPP-4 in overweight adults (NCT06827002), Phase 1/2, 248 participants; active, not recruiting. Published results claim semaglutide-like effects, from the supplier-linked group (Youovop et al., 2025).
  • Combination products for fracture healing: An unblinded trial, with an industry co-author, of Cissus with Boswellia serrata in 50 wrist-fracture patients reported faster bone union on X-rays (Mungara et al., 2026); a blinded, independently funded replication would strengthen or weaken the fracture claim.
  • Parathyroid hormone question: The 2025 finding of raised parathyroid hormone (Na Takuathung et al., 2025) needs long-term trials measuring hormone patterns and bone density; persistent elevation would weaken the case for long-term bone use.
  • Bone density over longer periods: The 24-week osteopenia trial showed slower turnover without density change (Benjawan et al., 2022); trials of 1–2 years are needed to see whether turnover changes translate into bone density or fracture outcomes.
  • Bioavailability-enhanced formulations: A self-emulsifying formulation raised absorption of Cissus constituents by about 76% in osteoporotic rats (Garg et al., 2024), which could improve efficacy but also alter the safety profile.
  • Completed implant-site trial: Osteogenic potential of Cissus in alveolar ridge distraction (NCT04669795), Phase 2, 20 participants, completed; reported denser bone around dental implants (Altaweel et al., 2021), awaiting larger confirmation.

Conclusion

Cissus quadrangularis is a grape-family vine with a long traditional record for mending bones, now sold mainly for bone healing, joint comfort and weight control. For health-focused adults willing to test and track, it presents a mixed but readable picture.

The strongest human evidence concerns body weight, blood fats and blood sugar, where several studies comparing it with an inactive dummy treatment report meaningful improvements. That evidence comes almost entirely from one research group working with the company that sells the tested extract, and several of the blood-fat results come from blends with other herbs, so independent confirmation is missing. Bone evidence is weaker: small fracture studies disagree, and a well-run study in women after menopause found slower bone breakdown and rebuilding but no change in bone density. Joint-pain relief in athletes rests on a single study without a comparison group.

Short-term use appears well tolerated, with mostly mild stomach upset, headache and poor sleep. The main open questions are a rise in the hormone that controls blood calcium, whose long-term effect on bone is unknown, and additive blood-sugar lowering alongside diabetes medication. No human safety data extend beyond six months, and product quality varies.

Overall, the evidence base is small, short and heavily shaped by commercial interests, while its low cost and patent-free status mean few independent funders study it.

Top - Benefits - Risks - Protocol